Estrogen and tibolone metabolite levels in blood and breast tissue of postmenopausal women recently diagnosed with early-stage breast cancer and treated with tibolone or placebo for 14 days

Reproductive Sciences

Volumn 14, Issue 2, 2007, Pages 151-159

  Kloosterboer, Helenius J ^a   Löfgren, Lars ^b   Von Schoulz, Eva ^c   Von Schoultz, Bo ^c   Verheul, Herman A M ^a,d  

^a Research and Development   (Netherlands)

^b ST GÖRAN S HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d NV ORGANON   (Netherlands)

Author keywords

Breast; Estrogen metabolites; Postmenopausal; Tibolone metabolites; Tissue level

Indexed keywords

3ALPHA HYDROXYTIBOLONE; 3ALPHA,17BETA TIBOLONE; 3BETA HYDROXYTIBOLONE; ANDROGEN; ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; PLACEBO; TIBOLONE; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; DELTA(4) TIBOLONE; DELTA(4)-TIBOLONE; DRUG DERIVATIVE; ESTRANE DERIVATIVE; PREGNANE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BLOOD EXAMINATION; BREAST CANCER; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGED; BLOOD; BREAST; BREAST TUMOR; DOUBLE BLIND PROCEDURE; MASS FRAGMENTOGRAPHY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

AGED; ANDROSTENOLS; BREAST; BREAST NEOPLASMS; CHROMATOGRAPHY, LIQUID; DOUBLE-BLIND METHOD; ESTRADIOL; ESTRENES; ESTRONE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NORPREGNENES; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 34648837212     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719106298679     Document Type: Article

References (40)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002 ; 288: 321-323.
2. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women study. Lancet. 2003 ; 362: 419-427.
3. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The WHI randomized controlled trial. JAMA. 2004 ; 291: 1701-1712.
4. Lundström E., Christow A., Kersemaekers W., et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol. 2002 ; 186: 717-722.
5. Palomba S., Di Carlo C., Morelli M., et al. Effect of tibolone on breast symptoms resulting from postmenopausal hormone replacement therapy. Maturitas. 2003 ; 45: 267-273.
6. Santen R. Menopausal therapies: their effects on mammographic density and breast cancer. Gynecol Endocrinol. 2005 ; 21: 12-16.
7. Verheul Ham, Coelingh-Bennink Hjt, Kenemans P., et al. Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies. Maturitas. 2000 ; 36: 1-17.
8. Chetrite GS, Cortes-Prieto J., Philippe JC, Wright F., Pasqualini JR Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal and cancerous, human breast tissues. J Steroid Biochem Mol Biol. 2000 ; 72: 23-27.
9. Pasqualini JR, Chetrite G., Blaker C., et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab. 1996 ; 81: 1460-1464.
10. Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol. 2003 ; 86: 245-253.
11. Mady EA, Ramadan EE-DH, Ossman AA. Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients. Dis Markers. 2000 ; 16: 151-157.
12. Morales L., Neven P., Paridaens R. Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting. Curr Opin Oncol. 2005 ; 17: 559-565.
13. Gupta P., Sturdee DW, Palin SL, et al. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric. 2006 ; 9: 49-58.
14. Kloosterboer HJ Tissue selective effects of tibolone on the breast. Maturitas. 2004 ; 49: S5 - S15.
15. Valdivia I., Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clin Drug Invest. 2000 ; 20: 101-107.
16. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, Panoulis Kpc, Kelekis DA, Creatsas GC Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause. 2002 ; 9: 110-116.
17. Bruce D., Rymer J., Robinson J., Millasseau S., Chowienczyk P. The long-term effects of tibolone on aortic stiffness and endothelial function. Climacteric. 2005 ; 8: 221-229.
18. Valdivia I., Campodonico I., Tapia A., Capetillo M., Espinoza A., Lavin P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril. 2004 ; 81: 617-623.
19. Gompel A., Chaouat M., Jacob D., Perrot J-Y., Kloosterboer HJ, Rostene W. In vitro studies of tibolone in breast cells. Fertil Steril. 2002 ; 78: 351-359.
20. Timmer CJ, Houwing NS Dose proportionality of three different doses of tibolone. Pharmacotherapy. 2002 ; 22: 6-13.
21. de Gooyer ME, Deckers GH, Schoonen WGEJ, Verheul HAM, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids. 2003 ; 68: 21-30.
22. Vos Rme, Krebbers Sfm, Verhoeven Chj, Delbressine Lpc. The in vivo human metabolism of tibolone. Drug Metab Dispos. 2002 ; 30: 106-112.
23. Chetrite G., Kloosterboer HJ, Pasqualini JR Effect of tibolone (Org OD14) and its metabolites on estrone sulfatase activity in MCF-7 and T47D mammary cancer cells. Anticancer Res. 1997 ; 17: 135-140.
24. Purohit A., Malini B., Hooymans C., Newman SP Inhibition of oestrone sulphatase activity by tibolone and its metabolites. Horm Metab Res. 2002 ; 1: 1-6.
25. Chetrite GS, Kloosterboer HJ, Philippe JC, Pasqualini JR Effects of Org OD14 (Livial®) and its metabolites on 17β-hydroxysteroid dehydrogenase activity in hormone dependent MCF-7 and TD-47D breast cancer cells. Anticancer Res. 1999 ; 19: 261-268.
26. de Gooyer ME, Overklift Vaupel Kleyn GT, Smits KC, Ederveen Agh, Verheul Ham, Kloosterboer HJ Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol. 2001 ; 183: 55-62.
27. Chetrite GS, Kloosterboer HJ, Philippe J-C., Pasqualini JR Effect of Org OD14 (Livial) and its metabolites on human estrogen sulfotransferase activity in the hormone-dependent MCF-7 and T47D, and the hormone-independent MDA-MB-231 breast cancer cell lines. Anticancer Res. 1999 ; 19: 269-276.
28. Pasqualini JR, Chetrite GS Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol. 2005 ; 93: 221-236.
29. Suzuki T., Nakata T., Miki Y., et al. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res. 2003 ; 63: 2762-2770.
30. Falany JL, Macrina N., Falany CN Sulfation of tibolone and tibolone metabolites by expressed human cytosolic sulfotransferases. J Steroid Biochem Mol Biol. 2004 ; 88: 383-339.
31. Dimitrakakis C., Zhou J., Bondy CA Androgens and mammary growth and neoplasia. Fertil Steril. 2002 ; 77: S26 - S33.
32. Dimitrakakis C., Zhou J., Wang J., et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause. 2003 ; 10: 292-298.
33. Hofling M., Carlstroem K., Svane G., Azavedo E., Kloosterboer HJ, von Schoultz B. Different effects of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels- an association with mammographic density. Gynecol Endocrinol. 2005 ; 20: 110-115.
34. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation: a revisit with a decade of progress. Pharm Res. 2000 ; 17: 1551-1557.
35. Guidance for Industry: Bioanalytical Methods Validation. Washington, DC: US Department of Health and Human Services, Food and Drug Administration ; 2001.
36. Kubista E., Dowsett M., Foidart J., et al. Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from a double-blind, placebo-controlled, randomized clinical trial (STEM) [abstract]. Eur J Cancer Suppl. 2006 ; 4: 126.
37. Doeren M., Rubig A., Coelingh Bennink H, Holzgreve W. Differential effects on androgen status in postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril. 2001 ; 75: 554-559.
38. Pluchino N., Genazzani AD, Bernardi F., et al. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels. Gynecol Endocrinol. 2005 ; 20: 144-149.
39. von Schoultz B. The effects of tibolone and estrogen-based HT on breast cell proliferation and mammographic density. Maturitas. 2004 ; 49: S16 - S21.
40. Chen FP, Cheung YC, Teng LF, Soong YK The relationship between mammographic density and duration of hormone therapy: effects of estrogen and estrogen-progestin. Hum Reprod. 2005 ; 20: 1741-1745.